Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.07 - $0.12 $9 - $16
140 Added 2.55%
5,632 $0
Q2 2023

Aug 15, 2023

BUY
$0.08 - $0.29 $1 - $6
21 Added 0.38%
5,492 $0
Q1 2023

May 12, 2023

SELL
$0.24 - $0.34 $438 - $621
-1,829 Reduced 25.05%
5,471 $1,000
Q4 2022

Feb 13, 2023

BUY
$0.18 - $0.3 $422 - $703
2,345 Added 47.33%
7,300 $1,000
Q3 2022

Nov 14, 2022

BUY
$0.24 - $0.71 $0 - $0
1 Added 0.02%
4,955 $1,000
Q2 2022

Aug 12, 2022

SELL
$0.63 - $1.1 $8 - $14
-13 Reduced 0.26%
4,954 $3,000
Q1 2022

May 16, 2022

SELL
$0.72 - $1.2 $13 - $22
-19 Reduced 0.38%
4,967 $4,000
Q3 2021

Nov 15, 2021

BUY
$1.53 - $1.85 $18 - $22
12 Added 0.24%
4,986 $8,000
Q2 2021

Aug 16, 2021

BUY
$1.55 - $2.15 $4 - $6
3 Added 0.06%
4,974 $9,000
Q1 2021

May 13, 2021

BUY
$1.99 - $2.9 $59 - $87
30 Added 0.61%
4,971 $10,000
Q4 2020

Feb 09, 2021

SELL
$1.88 - $2.84 $1,541 - $2,328
-820 Reduced 14.23%
4,941 $10,000
Q3 2020

Nov 05, 2020

BUY
$2.69 - $4.95 $2,377 - $4,375
884 Added 18.13%
5,761 $15,000
Q2 2020

Aug 13, 2020

SELL
$0.7 - $4.16 $2,137 - $12,700
-3,053 Reduced 38.5%
4,877 $20,000
Q1 2020

May 14, 2020

BUY
$0.76 - $1.54 $6,026 - $12,212
7,930 New
7,930 $6,000

Others Institutions Holding NAVB

About NAVIDEA BIOPHARMACEUTICALS, INC.


  • Ticker NAVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,150,900
  • Description
  • Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...
More about NAVB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.